RSV LID cp ΔM2-2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RSV LID cp ΔM2-2, covering 2018-07-02 to 2018-07-02. Get the full timeline:
Most recent: Clinical Trial Update: Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age [Phase 1]